Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2024-0223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Elliot B Tapper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Health Care Costs, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
While only recently approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), many patients with MASH have taken glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of comorbid Type 2 diabetes (T2D) or obesity. This real-world study evaluated treatment patterns, weight loss, healthcare resource utilization, and costs among patients with MASH who initiated GLP-1 RAs. Materials & methods: In a linked electronic health records (Veradigm Network EHR) and claims (Komodo Health) dataset, we identified adults (≥18 years old) with a MASH diagnosis who initiated GLP-1 RA treatment (1 July 2018 to 30 April 2023; index date = date of the first GLP-1 RA claim). Patients with other causes of liver disease or severe complications from MASH were excluded. We required ≥12 months of continuous enrollment pre- (baseline) and post-index (follow-up). Patients were stratified into high and low-dose subgroups. We also identified a comparator cohort of patients who initiated a different class of T2D medication (DPP4, SGLT2, or sulfonylurea) during the same time period. We captured patient characteristics, change in BMI, GLP-1 RA treatment patterns, liver-related events, healthcare utilization, and costs.
Results
We identified 10,316 patients with MASH who initiated a GLP-1 RA (high dose: 2043 [19.8%]; low dose: 8273 [80.2%]) and 2915 who initiated a non-GLP-1 RA T2D medication. GLP-1 RA users were 52.7 years old and 64.3% female. A 5.8% decrease in the percentage of patients with class III obesity was observed among GLP-1 RA users (10.7% among high-dose users; 0.8% among non-users). Overall, 56.1% of GLP-1 RA users discontinued during the 12-month follow-up. Total costs among GLP-1 RA users and non users were $20,912 and $19,019 in the baseline period and $27,586 and $24,917 in the follow-up period, respectively. Medical costs among GLP-1 RA users were $16,293 (baseline) and $16,886 (follow-up). Results were similar for high and low-dose subgroups.
Conclusion
Although some patients with MASH on GLP-1 RAs, particularly those taking higher dosages, may achieve weight loss, outcomes remain suboptimal with frequent discontinuation and high healthcare costs. Real-world GLP-1 RA utilization may be insufficient for resolving chronic metabolic issues, including MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
- Veradigm, Chicago, IL 60654, USA.
- Madrigal Pharmaceuticals, Inc., West Conshohocken, PA 19428, USA.
ORCID-Profile: Elliot B Tapper, Ni Zeng, Jessamine P Winer-Jones, Machaon Bonafede, Yestle Kim
Zitieren
APA
Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025). Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0223
Vancouver
Tapper EB, Ryan T, Zeng N, Carter R, Winer-Jones JP, Bonafede M, et al. Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0223
BibTeX
@article{Tapper2025,
author = {Tapper, Elliot B and Ryan, Taylor and Zeng, Ni and Carter, Renee and Winer-Jones, Jessamine P and Bonafede, Machaon and Kim, Yestle},
title = {Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2024-0223}
}
EUVIMED